- Home
- NTHI vs TRT Comparison
NTHI vs TRT Comparison
Compare NTHI & TRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | TRT |
|---|---|---|
| Founded | 2008 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.5M | 109.1M |
| IPO Year | 2023 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NTHI | TRT |
|---|---|---|
| Price | $4.23 | $11.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 180.6K | ★ 283.9K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $39,990.00 | ★ $32,462,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $573.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.01 | $4.42 |
| 52 Week High | $12.99 | $21.38 |
Technical Indicators
Market Signals| Indicator | NTHI | TRT |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 57.38 |
| Support Level | $3.01 | $9.15 |
| Resistance Level | $4.59 | $12.94 |
| Average True Range (ATR) | 0.44 | 0.77 |
| MACD | 0.10 | 0.21 |
| Stochastic Oscillator | 58.70 | 90.00 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
About TRT Trio-Tech International
Trio-Tech International is a provider of reliability test equipment and services to the semiconductor and other industries. Its customers are from automotive electronics, industrial electronics, computing and data storage, consumer electronics, and communication markets. The company operated its business in two segments: Semiconductor Back-end Solutions and Industrial Electronics. Geographically, the company operates in the United States (U.S), Singapore, Malaysia, Thailand and China.